Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry

American Heart Journal

Volumn 181, Issue , 2016, Pages 83-91

  Proietti, Marco ^a   Laroche, Cécile ^b   Drozd, Marcin ^c,d   Vijgen, Johan ^e   Cozma, Dragos C ^f   Drozdz, Jaroslaw ^g   Maggioni, Aldo P ^b,h   Boriani, Giuseppe ^i,j   Lip, Gregory Y H ^a,k  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b European Society of Cardiology   (France)

^c MILITARY HOSPITAL   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e Jessa Hospitlas ^*  (Belgium)

^f VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h ANMCO RESEARCH CENTER   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k AALBORG UNIVERSITY   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADVERSE OUTCOME; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; THROMBOEMBOLISM; ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HEART ARREST; HEMORRHAGE; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PILOT STUDY; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMBOLISM; REGISTER; RISK FACTOR; STATISTICAL MODEL; STROKE; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART ARREST; HEART FAILURE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PILOT PROJECTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMBOLISM; REGISTRIES; RISK FACTORS; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84987623379     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.08.011     Document Type: Article

References (32)

1. 1. Fabbri, LM, Hurd, SS, Global strategy for the diagnosis, management and prevention of COPD: 2003 update [Internet]. Eur Respir J 22:1 (2003), 1–2 Available from: http://www.ersj.org.uk/cgi/content/full/22/1/1.
2. 2. Rycroft, CE, Heyes, A, Lanza, L, et al. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis 7 (2012), 457–494 [Internet, cited 2016 Feb 14, Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3422122&tool=pmcentrez&rendertype=abstract.
3. 3. Global strategy for the diagnosis, management and prevention of COPD. GOLD [Internet]. 2015, 1–23 [Available from: http://www.goldcopd.org/].
4. 4. Mozaffarian, D, Benjamin, EJ, Go, AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133:4 (2015), e38–360 [Internet, [cited 2015 Dec 19] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26673558.
5. 5. Chen, W, Thomas, J, Sadatsafavi, M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 3:8 (2015), 631–639 [Internet, [cited 2016 Mar 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26208998].
6. 6. Konecny, T, Park, JY, Somers, KR, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 114:2 (2014), 272–277 [Internet, [cited 2015 Dec 7] Available from: http://www.sciencedirect.com/science/article/pii/S0002914914010443].
7. 7. Li, J, Agarwal, SK, Alonso, A, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the atherosclerosis risk in communities (ARIC) study. Circulation 129:9 (2014), 971–980 [Internet, [cited 2016 Mar 7] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3963836&tool=pmcentrez&rendertype=abstract].
8. 8. Camm, AJ, Kirchhof, P, Lip, GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 31:19 (2010), 2369–2429 [Internet, [cited 2014 Jul 10] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20876603].
9. 9. Huang, B, Yang, Y, Zhu, J, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc 15:8 (2014), 576–581 [Internet, [cited 2015 Dec 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24894999].
10. 10. Durheim, MT, Cyr, DD, Lopes, RD, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial. Int J Cardiol 202 (2015), 589–594 [Internet, [cited 2015 Nov 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26447668].
11. 11. Sidney, S, Sorel, M, Quesenberry, CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 128:4 (2005), 2068–2075 [Internet, [cited 2016 Feb 5], Available from: http://www.ncbi.nlm.nih.gov/pubmed/16236856].
12. 12. Gu, J, Liu, X, Tan, H, et al. Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. J Cardiovasc Electrophysiol 24:2 (2013), 148–154 [Internet, [cited 2016 Mar 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23066893].
13. 13. de Vos, CB, Pisters, R, Nieuwlaat, R, et al. Progression from paroxysmal to persistent atrial fibrillation. Clinical correlates and prognosis. J Am Coll Cardiol 55:8 (2010), 725–731 [Internet, [cited 2016 Feb 29] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20170808].
14. 14. Lip, GYH, Laroche, C, Dan, G-A, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16:3 (2014), 308–319 [Internet, [cited 2015 Apr 15] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24351881].
15. 15. Lip, GYH, Laroche, C, Ioachim, PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 35:47 (2014 Dec 14), 3365–3376 [Internet, [cited 2015 Jun 17] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25176940].
16. 16. Lip, GYH, Laroche, C, Popescu, MI, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 17 (2015), 1777–1786 [Internet, [cited 2015 Sep 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26321406].
17. 17. Lip, GYH, Nieuwlaat, R, Pisters, R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:2 (2010), 263–272 [Internet, [cited 2014 Jul 10] Available from: http://www.ncbi.nlm.nih.gov/pubmed/19762550].
18. 18. Pisters, R, Lane, DA, Nieuwlaat, R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:5 (2010), 1093–1100 [Internet, [cited 2014 Oct 17] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20299623.
19. 19. January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:23 (2014), e199–e267 [Internet, [cited 2014 Dec 2] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24682347].
20. 20. Hawkins, NM, Virani, S, Ceconi, C, Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 34:36 (2013), 2795–2803 [Internet, [cited 2016 Mar 18] Available from: http://eurheartj.oxfordjournals.org/content/34/36/2795].
21. 21. Lip, GYH, Ponikowski, P, Andreotti, F, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 14:7 (2012), 681–695 [Internet, [cited 2016 Mar 18], Available from: http://www.ncbi.nlm.nih.gov/pubmed/22611046].
22. 22. Mannino, DM, Thorn, D, Swensen, A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32:4 (2008), 962–969 [Internet, [cited 2016 Feb 11] Available from: http://www.ncbi.nlm.nih.gov/pubmed/18579551].
23. 23. Ss, S, Ormiston, T, Salpeter, E, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev, 2005, CD003566 [Internet [cited 2016 Mar 7, 1)Available from: http://www.ncbi.nlm.nih.gov/pubmed/16235327].
24. 24. Rutten, FH, Zuithoff, NPA, Hak, E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 170:10 (2010), 880–887 [Internet, [cited 2016 Apr 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20498416].
25. 25. Bhatt, SP, Wells, JM, Kinney, GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 71:1 (2016), 8–14 [Internet, [cited 2016 Apr 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26283710].
26. 26. Jabbour, A, Macdonald, PS, Keogh, AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease. A randomized crossover trial. J Am Coll Cardiol 55:17 (2010), 1780–1787 [Internet, [cited 2016 Mar 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20413026.
27. 27. Pokorney, SD, Piccini, JP, Stevens, SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc, 5(3), 2016, 002197 [Internet, [cited 2016 Mar 11] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26955859].
28. 28. Proietti, M, Laroche, C, Opolski, G, et al. “Real-world” atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace, 2016 pii: euw112. [Epub ahead of print], [Internet, [cited 2016 Jun 29] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27194538].
29. 29. Proietti, M, Raparelli, V, Olshansky, B, et al. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol 105 (2015), 412–420 [Internet, [cited 2015 Nov 23] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26525391].
30. 30. Rothnie, KJ, Yan, R, Smeeth, L, et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open, 5(9), 2015, e007824 [Internet, [cited 2016 Jun 29] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26362660].
31. 31. Rothnie, KJ, Quint, JK, Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. Eur Hear J - Qual Care Clin Outcomes, 2016, The Oxford University Press, qcw005 [Internet, Available from: http://ehjqcco.oxfordjournals.org/content/early/2016/02/25/ehjqcco.qcw005.abstract].
32. 32. de Lucas-Ramos, P, Izquierdo-Alonso, JL, Rodriguez-Gonzalez Moro, JM, et al. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis 7 (2012), 679–686 [Internet, [cited 2016 Jun 29] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23055717.